Coherus Biosciences | Frais De Vente Et D'Administration





Frais De Vente Et D'Administration Changement Date
AbbVie USD 3.89B 325M 2025-12
Acadia Pharmaceuticals USD 146.73M 21.82M 2025-12
Akebia Therapeutics USD 25.74M 1.93M 2025-03
ALKERMES USD 187.2M 15.43M 2025-12
Alnylam Pharmaceuticals USD 285.06M 22.47M 2025-12
Amarin USD 17.94M 17.86M 2025-09
Amgen USD 1.94B 237M 2025-12
Baxter International USD 761M 53M 2025-12
Biogen USD 545.2M 38.6M 2025-09
BioMarin Pharmaceutical USD 322.21M 98.79M 2025-12
Bristol-Myers Squibb USD 2.18B 392M 2025-12
Coherus Biosciences USD 26.02M 8.57M 2025-03
Eli Lilly USD 3.13B 391.3M 2025-12
Fujifilm JPY 215.83B 2.93B 2025-12
Gilead Sciences USD 1.78B 425M 2025-12
Ironwood Pharmaceuticals USD 33.33M 2.78M 2024-12
Merck USD 2.85B 215M 2025-12
Myriad Genetics USD 129M 1.3M 2025-09
Pacira USD 91.87M 70K 2025-12
Perrigo USD 255.9M 10.2M 2025-12
Pfizer USD 4.08B 894M 2025-12
PTC Therapeutics USD 87.2M 3.15M 2025-12
Regeneron Pharmaceuticals USD 775M 117.2M 2025-12
Sarepta Therapeutics USD 105.38M 28.27M 2025-12
Teva Pharmaceutical Industries USD 1.12B 147M 2025-12
Vertex Pharmaceuticals USD 487M 41.9M 2025-12
Xencor USD 17.04M 70.74M 2025-12
Zoetis USD 619M 40M 2025-12


Coherus Biosciences Frais De Vente Et D'Administration - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Mar 2026.